1
|
Ortiz JR, Neuzil KM. Influenza vaccine programs for children in low- and middle-income countries: current status and way forward. Expert Rev Vaccines 2019; 18:711-724. [DOI: 10.1080/14760584.2019.1635462] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Justin R Ortiz
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Kathleen M Neuzil
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA
| |
Collapse
|
2
|
Rudenko L, Kiseleva I, Krutikova E, Stepanova E, Rekstin A, Donina S, Pisareva M, Grigorieva E, Kryshen K, Muzhikyan A, Makarova M, Sparrow EG, Torelli G, Kieny MP. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. PLoS One 2018; 13:e0208028. [PMID: 30507951 PMCID: PMC6277076 DOI: 10.1371/journal.pone.0208028] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 11/10/2018] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND AND AIM The majority of seasonal influenza vaccines are trivalent, containing two A virus strains (H1N1 and H3N2) and one B virus strain. The co-circulation of two distinct lineages of B viruses can lead to mismatch between the influenza B virus strain recommended for the trivalent seasonal vaccine and the circulating B virus. This has led some manufacturers to produce quadrivalent influenza vaccines containing one strain from each B lineage in addition to H1N1 and H3N2 strains. However, it is also important to know whether vaccines containing a single influenza B strain can provide cross-protectivity against viruses of the antigenically distinct lineage. The aim of this study was to assess in naïve ferrets the potential cross-protective activity of trivalent live attenuated influenza vaccine (T-LAIV) against challenge with a heterologous wild-type influenza B virus belonging to the genetically different lineage and to compare this activity with effectiveness of quadrivalent LAIV (Q-LAIV) in the ferret model. METHODS AND RESULTS Ferrets were vaccinated with either one dose of trivalent LAIV containing B/Victoria or B/Yamagata lineage virus, or quadrivalent LAIV (containing both B lineages), or placebo. They were then challenged with B/Victoria or B/Yamagata lineage wild-type virus 28 days after vaccination. The ferrets were monitored for clinical signs and morbidity. Nasal swabs and lung tissue samples were analyzed for the presence of challenge virus. Antibody response to vaccination was assessed by routine hemagglutination inhibition assay. All LAIVs tested were found to be safe and effective against wild-type influenza B viruses based on clinical signs, and virological and histological data. The absence of interference between vaccine strains in trivalent and quadrivalent vaccine formulations was confirmed. Trivalent LAIVs were shown to have the potential to be cross-protective against infection with genetically different influenza B/Victoria and B/Yamagata lineages. CONCLUSIONS In this ferret model, quadrivalent vaccine provided higher protection to challenge against both B/Victoria and B/Yamagata lineage viruses. However, T-LAIV provided some cross-protection in the case of a mismatch between circulating and vaccine type B strains. Notably, B/Victoria-based T-LAIV was more protective compared to B/Yamagata-based T-LAIV.
Collapse
MESH Headings
- Administration, Intranasal
- Animals
- Antibodies, Viral/blood
- Cross Protection/genetics
- Cross Protection/immunology
- Disease Models, Animal
- Female
- Ferrets
- Humans
- Immunogenicity, Vaccine
- Influenza A Virus, H1N1 Subtype/genetics
- Influenza A Virus, H1N1 Subtype/immunology
- Influenza A Virus, H1N1 Subtype/pathogenicity
- Influenza A Virus, H3N2 Subtype/genetics
- Influenza A Virus, H3N2 Subtype/immunology
- Influenza A Virus, H3N2 Subtype/pathogenicity
- Influenza B virus/genetics
- Influenza B virus/immunology
- Influenza B virus/pathogenicity
- Influenza Vaccines/administration & dosage
- Influenza Vaccines/immunology
- Influenza, Human/blood
- Influenza, Human/immunology
- Influenza, Human/prevention & control
- Influenza, Human/virology
- Vaccination/methods
- Vaccines, Attenuated/administration & dosage
- Vaccines, Attenuated/immunology
Collapse
Affiliation(s)
- Larisa Rudenko
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Irina Kiseleva
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Elena Krutikova
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Ekaterina Stepanova
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Andrey Rekstin
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Svetlana Donina
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Maria Pisareva
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Elena Grigorieva
- Department of Virology, Institute of Experimental Medicine, St Petersburg, Russia
| | - Kirill Kryshen
- Department of Toxicology and Microbiology, Institute of Preclinical Research Ltd, St Petersburg, Russia
| | - Arman Muzhikyan
- Department of Toxicology and Microbiology, Institute of Preclinical Research Ltd, St Petersburg, Russia
| | - Marina Makarova
- Department of Toxicology and Microbiology, Institute of Preclinical Research Ltd, St Petersburg, Russia
| | - Erin Grace Sparrow
- Universal Health Coverage and Health Systems, World Health Organization, Geneva, Switzerland
| | - Guido Torelli
- Universal Health Coverage and Health Systems, World Health Organization, Geneva, Switzerland
| | - Marie-Paule Kieny
- International Institutional Cooperation, Institut national de la santé et de la recherche médicale (INSERM), Paris, France
| |
Collapse
|
3
|
Rudenko L, Kiseleva I, Krutikova E, Stepanova E, Isakova-Sivak I, Donina S, Rekstin A, Pisareva M, Bazhenova E, Kotomina T, Katelnikova A, Muzhikyan A, Makarov V, Sparrow EG, Torelli G. Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets. Vaccines (Basel) 2018; 6:vaccines6040074. [PMID: 30388790 PMCID: PMC6313887 DOI: 10.3390/vaccines6040074] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 09/21/2018] [Accepted: 09/27/2018] [Indexed: 12/11/2022] Open
Abstract
Influenza H7N9 virus is a potentially pandemic subtype to which most people are immunologically naïve. To be better prepared for the potential occurrence of an H7N9 pandemic, in 2017 the World Health Organization recommended developing candidate vaccine viruses from two new H7N9 viruses, A/Guangdong/17SF003/2016 (A/GD) and A/Hong Kong/125/2017 (A/HK). This report describes the development of live attenuated influenza vaccine (LAIV) candidates against A/GD and A/HK viruses and study of their safety and immunogenicity in the ferret model in order to choose the most promising one for a phase I clinical trial. The A/HK-based vaccine candidate (A/17/HK) was developed by classical reassortment in eggs. The A/GD-based vaccine candidate (A/17/GD) was generated by reverse genetics. Ferrets were vaccinated with two doses of LAIV or phosphate-buffered saline. Both H7N9 LAIVs tested were safe for ferrets, as shown by absence of clinical signs, and by virological and histological data; they were immunogenic after a single vaccination. These results provide a compelling argument for further testing of these vaccines in volunteers. Since the A/HK virus represents the cluster that has caused the majority of human cases, and because the A/HK-based LAIV candidate was developed by classical reassortment, this is the preferred candidate for a phase I clinical trial.
Collapse
Affiliation(s)
- Larisa Rudenko
- Institute of Experimental Medicine, St. Petersburg 197376, Russia.
| | - Irina Kiseleva
- Institute of Experimental Medicine, St. Petersburg 197376, Russia.
| | - Elena Krutikova
- Institute of Experimental Medicine, St. Petersburg 197376, Russia.
| | | | | | - Svetlana Donina
- Institute of Experimental Medicine, St. Petersburg 197376, Russia.
| | - Andrey Rekstin
- Institute of Experimental Medicine, St. Petersburg 197376, Russia.
| | - Maria Pisareva
- Institute of Experimental Medicine, St. Petersburg 197376, Russia.
| | | | - Tatiana Kotomina
- Institute of Experimental Medicine, St. Petersburg 197376, Russia.
| | | | - Arman Muzhikyan
- Institute of Preclinical Research Ltd., St. Petersburg 188663, Russia.
| | - Valery Makarov
- Institute of Preclinical Research Ltd., St. Petersburg 188663, Russia.
| | | | - Guido Torelli
- World Health Organization, 1211 Geneva, Switzerland.
| |
Collapse
|
4
|
Huang SY, Lin MH, Chen YH, Lai CC, Lee MS, Hu AYC, Sung WC. Application of stable isotope dimethyl labeling for MRM based absolute antigen quantification of influenza vaccine. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1104:40-48. [PMID: 30428430 DOI: 10.1016/j.jchromb.2018.09.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Revised: 09/11/2018] [Accepted: 09/18/2018] [Indexed: 12/23/2022]
Abstract
Determining the precursor/product ion pair and optimal collision energy are the critical steps for developing a multiple reaction monitoring (MRM) assay using triple quadruple mass spectrometer for protein quantitation. In this study, a platform consisting of stable isotope dimethyl labeling coupled with triple-quadruple mass spectrometer was used to quantify the protein components of the influenza vaccines. Dimethyl labeling of both the peptide N-termini and the ϵ-amino group of lysine residues was achieved by reductive amination using formaldehyde and sodium cyanoborohydrate. Dimethylated peptides are known to exhibit dominant a1 ions under gas phase fragmentation in a mass spectrometer. These a1 ions can be predicted from the peptide N-terminal amino acids, and their signals do not vary significantly across a wide range of collision energies, which facilitates the determination of MRM transition settings for multiple protein targets. The intrinsic a1 ions provide sensitivity for acquiring MRM peaks that is superior to that of the typical b/y ions used for native peptides, and they also provided good linearity (R2 ≥ 0.99) at the detected concentration range for each peptide. These features allow for the simultaneous quantification of hemagglutinin and neuraminidase in vaccines derived from either embryo eggs or cell cultivation. Moreover, the low abundant ovalbumin residue originated from the manufacturing process can also be determined. The results demonstrate that the stable isotope dimethyl labeling coupled with MRM Mass spectrometry screening of a1 ions (i.e., SIDa-MS) can be used as a high-throughput platform for multiple protein quantification of vaccine products.
Collapse
Affiliation(s)
| | - Min-Han Lin
- National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology, Miaoli 350, Taiwan
| | - Yo-Hsuan Chen
- National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology, Miaoli 350, Taiwan
| | - Chia-Chun Lai
- National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology, Miaoli 350, Taiwan
| | - Min-Shi Lee
- National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology, Miaoli 350, Taiwan
| | - Alan Yung-Chih Hu
- National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology, Miaoli 350, Taiwan
| | - Wang-Chou Sung
- National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology, Miaoli 350, Taiwan.
| |
Collapse
|
5
|
Attaran H, Nili H, Gholamhossein Gudarzi B, He HX. Efficacy of prokaryotic and eukaryotic recombinant fusion proteins (M2e-carliticulin) as an influenza universal vaccine in mice C57Bl/6. Future Virol 2018. [DOI: 10.2217/fvl-2018-0053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Aim: The aim of this work was a preliminary study on the immunogenicity and protectivity effect of eukaryotic and prokaryotic expressed M2e-Carliticulin (CRT) in the experimental mice. Materials & methods: We constructed and expressed M2e-CRT in Escherichia coli and Pichia pastoris. Then we evaluated the immunological responses and virus challenge following injection of M2e-CRT fusion protein, expressed in E. coli and P. pastoris as a recombinant protein vaccine. According to this issue, a prime-boost administration of M2e-CRT by subcutaneous route in C57Bl/6 mouse model was done. Results: Both fusion proteins induced comparable immunologic responses. Conclusion: But because of easier and cheaper purification in prokaryote system this has led to the M2e-CRT as a vaccine candidate in prokaryote system compared with eukaryotic is preferred.
Collapse
Affiliation(s)
- Hamidreza Attaran
- National Research Center for Wildlife-borne Diseases Institute of Zoology, Chinese Academy of Sciences, Beijing, PR China
- Avian Diseases Research Center, Faculty of Veterinary Medicine, University of Shiraz, Shiraz 71345-1731, Iran
| | - Hassan Nili
- Avian Diseases Research Center, Faculty of Veterinary Medicine, University of Shiraz, Shiraz 71345-1731, Iran
- Department of Clinical Studies, School of Veterinary Medicine, Shahrekord University, Shahrekord 88186/34141, Iran
| | - Bahman Gholamhossein Gudarzi
- Department of Clinical Studies, School of Veterinary Medicine, Shahrekord University, Shahrekord 88186/34141, Iran
| | - Hong-Xuan He
- National Research Center for Wildlife-borne Diseases Institute of Zoology, Chinese Academy of Sciences, Beijing, PR China
| |
Collapse
|
6
|
Ortiz JR, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz JM, Madhi SA, Neuzil KM, Rimmelzwaan GF, Southern J, Spiro DJ, Hombach J. Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016. Vaccine 2017; 36:932-938. [PMID: 29221895 DOI: 10.1016/j.vaccine.2017.11.061] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 11/17/2017] [Indexed: 12/26/2022]
Abstract
In August 2016, the World Health Organization (WHO) convened the "Eighth meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses" to discuss the regulatory requirements and pathways for licensure of next-generation influenza vaccines, and to identify areas where WHO can promote the development of such vaccines. Participants included approximately 120 representatives of academia, the vaccine industry, research and development funders, and regulatory and public health agencies. They reviewed the draft WHO preferred product characteristics (PPCs) of vaccines that could address prioritized unmet public health needs and discussed the challenges facing the development of such vaccines, especially for low- and middle-income countries (LMIC). They defined the data desired by public-health decision makers globally and explored how to support the progression of promising candidates into late-stage clinical trials and for all countries. This report highlights the major discussions of the meeting.
Collapse
Affiliation(s)
- Justin R Ortiz
- Initiative for Vaccine Research, World Health Organization (WHO), Geneva, Switzerland.
| | - Julian Hickling
- Working in Tandem Ltd, Cambridge, Northern Ireland, United Kingdom.
| | - Rebecca Jones
- Working in Tandem Ltd, Cambridge, Northern Ireland, United Kingdom.
| | - Armen Donabedian
- Biomedical Advanced Research and Development Authority, United States Department of Health and Human Services, Washington DC, United States.
| | - Othmar G Engelhardt
- Division of Virology, National Institute for Biological Standards and Control, A Centre of the Medicines and Healthcare products Regulatory Agency, Potters Bar, Hertfordshire, United Kingdom.
| | - Jacqueline M Katz
- Influenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, United States.
| | - Shabir A Madhi
- Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
| | - Kathleen M Neuzil
- Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, United States.
| | - Guus F Rimmelzwaan
- Erasmus Medical Center, Department of Viroscience, Rotterdam, The Netherlands.
| | - James Southern
- Advisor to Medicines Control Council, Simon's Town, South Africa.
| | - David J Spiro
- National Institutes of Health, Bethesda, United States.
| | - Joachim Hombach
- Initiative for Vaccine Research, World Health Organization (WHO), Geneva, Switzerland.
| |
Collapse
|
7
|
Vincent AL, Perez DR, Rajao D, Anderson TK, Abente EJ, Walia RR, Lewis NS. Influenza A virus vaccines for swine. Vet Microbiol 2017; 206:35-44. [DOI: 10.1016/j.vetmic.2016.11.026] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 11/20/2016] [Accepted: 11/23/2016] [Indexed: 12/09/2022]
|
8
|
Di Mario G, Sciaraffia E, Facchini M, Gubinelli F, Soprana E, Panigada M, Bernasconi V, Garulli B, Siccardi A, Donatelli I, Castrucci MR. Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. Pathog Glob Health 2017; 111:76-82. [PMID: 28079473 PMCID: PMC5375616 DOI: 10.1080/20477724.2016.1275465] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The emergence of novel strains of influenza A viruses with hemagglutinins (HAs) that are antigenically distinct from those circulating in humans, and thus have pandemic potential, pose concerns and call for the development of more broadly protective influenza vaccines. In the present study, modified vaccinia virus Ankara (MVA) encoding internal influenza antigens were evaluated for their immunogenicity and ability to protect HLA-A2.1 transgenic (AAD) mice from infection with influenza viruses. METHODS MVAs expressing NP (MVA-NP), M1 (MVA-M1) or polymerase PB1 (MVA-PB1) of A/California/4/09 (CA/09) virus were generated and used to immunize AAD mice. Antibodies and CD8+T cell responses were assessed by ELISA and ELISPOT, respectively, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus. RESULTS CD8+T cells specific to immunodominant and subdominant epitopes on the internal influenza proteins were elicited by MVA-based vectors in AAD mice, whereas influenza-specific antibodies were detected only in MVA-NP-immunized mice. Both M1- and NP-based MVA vaccines, regardless of whether they were applied individually or in combination, conferred protection against lethal influenza virus challenge. CONCLUSION Our data further emphasize the promising potential of MVA vector expressing internal antigens toward the development of a universal influenza vaccine.
Collapse
Affiliation(s)
- Giuseppina Di Mario
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Ester Sciaraffia
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Marzia Facchini
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Francesco Gubinelli
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | - Elisa Soprana
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | - Maddalena Panigada
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | | | - Bruno Garulli
- c Department of Biology and Biotechnology "Charles Darwin" , Sapienza University of Rome , Rome , Italy
| | - Antonio Siccardi
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | - Isabella Donatelli
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Maria R Castrucci
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| |
Collapse
|
9
|
Liu H, Frijlink HW, Huckriede A, van Doorn E, Schmidt E, Leroy O, Rimmelzwaan G, McCullough K, Whelan M, Hak E. Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project. Vaccine 2016; 34:5845-5854. [PMID: 27793486 DOI: 10.1016/j.vaccine.2016.10.040] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 10/11/2016] [Accepted: 10/17/2016] [Indexed: 11/26/2022]
Abstract
Due to influenza viruses continuously displaying antigenic variation, current seasonal influenza vaccines must be updated annually to include the latest predicted strains. Despite all the efforts put into vaccine strain selection, vaccine production, testing, and administration, the protective efficacy of seasonal influenza vaccines is greatly reduced when predicted vaccine strains antigenically mismatch with the actual circulating strains. Moreover, preparing for a pandemic outbreak is a challenge, because it is unpredictable which strain will cause the next pandemic. The European Commission has funded five consortia on influenza vaccine development under the Seventh Framework Programme for Research and Technological Development (FP7) in 2013. The call of the EU aimed at developing broadly protective influenza vaccines. Here we review the scientific strategies used by the different consortia with respect to antigen selection, vaccine delivery system, and formulation. The issues related to the development of novel influenza vaccines are discussed.
Collapse
Affiliation(s)
- Heng Liu
- Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
| | - Henderik W Frijlink
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| | - Anke Huckriede
- Department of Medical Microbiology, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| | - Eva van Doorn
- Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| | - Ed Schmidt
- Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| | - Odile Leroy
- European Vaccine Initiative (EEIG), Im Neuerheimer Feld 307, 69120 Heidelberg, Germany
| | - Guus Rimmelzwaan
- Erasmus University Medical Center Rotterdam (EMC), Dr. Molewaterplein 50, 3015 CE Rotterdam, The Netherlands
| | - Keneth McCullough
- The Institute of Virology and Immunology (IVI), Sensemattstrasse 293, CH-3147 Mittelhäusern, Switzerland
| | - Mike Whelan
- iQur Limited, London Bioscience Innovation Centre, 2 Royal College Street, NW1-0NH London, United Kingdom
| | - Eelko Hak
- Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
| |
Collapse
|
10
|
Cox NJ, Hickling J, Jones R, Rimmelzwaan GF, Lambert LC, Boslego J, Rudenko L, Yeolekar L, Robertson JS, Hombach J, Ortiz JR. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014. Vaccine 2015; 33:6503-10. [PMID: 26478203 PMCID: PMC8218335 DOI: 10.1016/j.vaccine.2015.10.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 09/02/2015] [Accepted: 10/06/2015] [Indexed: 11/22/2022]
Abstract
On 5-7 May 2014, the World Health Organization (WHO) convened the second integrated meeting on "influenza vaccines that induce broadly protective and long-lasting immune responses". Around 100 invited experts from academia, the vaccine industry, research and development funders, and regulatory and public health agencies attended the meeting. Areas covered included mechanisms of protection in natural influenza-virus infection and vaccine-induced immunity, new approaches to influenza-vaccine design and production, and novel routes of vaccine administration. A timely focus was on how this knowledge could be applied to both seasonal influenza and emerging viruses with pandemic potential such as influenza A (H7N9), currently circulating in China. Special attention was given to the development of possible universal influenza vaccines, given that the Global Vaccine Action Plan calls for at least one licensed universal influenza vaccine by 2020. This report highlights some of the topics discussed and provides an update on studies published since the report of the previous meeting.
Collapse
Affiliation(s)
- Nancy J Cox
- Influenza Division, National Center for Infectious Diseases, 1600 Clifton Road NE, Atlanta, GA 30333, United States
| | | | - Rebecca Jones
- Working in Tandem Ltd, Cambridge CB1 7AB, United Kingdom
| | - Guus F Rimmelzwaan
- Department of Virology, Erasmus Medical Center, Dr Molewaterplein 50, Rotterdam CE 3015, The Netherlands
| | - Linda C Lambert
- Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID/NIH/DHHS, 5601 Fishers Lane, Bethesda, MD 20892, United States
| | - John Boslego
- PATH, 445 Massachusetts Avenue, NW Suite 1000, Washington, DC 20001, United States
| | - Larisa Rudenko
- Institute of Experimental Medicine, Russian Academy of Medical Sciences, 12 Acad. Pavlov Street, St Petersburg 197376, Russian Federation
| | - Leena Yeolekar
- Vaccine Production, Serum Institute of India, 212/2 Hadapsar, Pune, India
| | | | - Joachim Hombach
- Initiative for Vaccine Research (IVR), Immunization, Vaccines and Biologicals (IVB), World Health Organization, Switzerland
| | - Justin R Ortiz
- Initiative for Vaccine Research (IVR), Immunization, Vaccines and Biologicals (IVB), World Health Organization, Switzerland
| |
Collapse
|